EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Rare Diseases

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Rare Diseases

by Elena Iemma | Sep 22, 2023

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Rare Diseases
iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology

iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology

by Elena Iemma | Sep 22, 2023

iVAX for antigen discovery, vaccine design, diagnostics, and epidemiology
Innovative preclinical assessment tools for safety and efficacy of protein and peptide therapeutics… Of Peptides and P-ANDAS

Innovative preclinical assessment tools for safety and efficacy of protein and peptide therapeutics… Of Peptides and P-ANDAS

by Elena Iemma | Sep 22, 2023

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics… of Peptides and P-ANDAS
In silico immunogenicity risk assessment for fusion proteins and novel antibody modalities

In silico immunogenicity risk assessment for fusion proteins and novel antibody modalities

by Elena Iemma | Sep 21, 2023

In silico immunogenicity risk assessment for fusion proteins and novel antibody modalities
Sequence-based evaluation of the immune landscape of seasonal influenza virus A(H3N2) virus

Sequence-based evaluation of the immune landscape of seasonal influenza virus A(H3N2) virus

by Elena Iemma | Sep 21, 2023

Sequence-based evaluation of the immune landscape of seasonal influenza virus A(H3N2) virus
« Older Entries

Recent Posts

  • Dreaming of Peptides (and Hello from Tokyo!)
  • Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach
  • Throw Down a Challenge
  • EpiVax Birthday Cake Alert! | Fall ’23 Travel Schedule
  • Lab Day at the Beach 2023 *Pictures!*

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562